Unbelievable Growth! Sanofi India's Q3 Profit Jumps 40% – See How They Did It!

Healthcare/Biotech

|

Updated on 13 Nov 2025, 11:04 am

Sanofi Consumer Healthcare India Limited announced robust financial results for its third quarter, reporting a significant 40% jump in profit to ₹62.9 crore. Revenue also saw a substantial increase of 46%, reaching ₹233.9 crore.

The primary drivers for this impressive performance were a solid 20% growth in domestic sales and an extraordinary surge in export sales, which surpassed tenfold due to a lower base in the prior year. Himanshu Bakshi, managing director, highlighted the strong domestic business and the additional boost from exports. He also confirmed the successful re-establishment of market presence for all voluntarily recalled products within the year.

For the nine-month period, the company's revenue grew by 13% to ₹672.4 crore. However, Sanofi Consumer Healthcare noted that the figures for both the quarter and the nine-month period are not directly comparable with the previous year. This is attributed to the demerger of Sanofi Consumer Healthcare India as a distinct legal entity from Sanofi India Limited, which became effective last year, and the voluntary recall of certain product variants such as Depura Adult, Depura Kids, Allegra Suspension, and Combiflam Suspension. The company has since successfully relaunched these products, with Depura Adult and Combiflam Suspension reintroduced in the quarters ending March 2025 and June 2025 respectively. Allegra Suspension and Depura Kids were relaunched in the quarter ending September 2025.

**Impact** This news has a positive impact on Sanofi Consumer Healthcare India Limited's stock performance and provides a positive outlook for the Indian consumer healthcare sector. Investors might see this as a sign of strong operational recovery and growth potential. The stock price reacted positively, gaining 7.34%. Rating: 7/10

**Difficult Terms**: * **Demerger**: The separation of a company's business into two or more distinct entities. In this case, Sanofi Consumer Healthcare India Limited was separated from Sanofi India Limited. * **Voluntary Recall**: When a company, on its own initiative, withdraws a product from the market due to safety concerns or quality issues, rather than being forced by a regulatory body. * **Scheme of Arrangement**: A legal process in corporate law that allows companies to restructure, merge, or demerge. * **National Company Law Tribunal (NCLT)**: A quasi-judicial body in India that adjudicates corporate disputes.